|
Real-time
Euronext Paris
17:11:54 10/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.7960 EUR | -1.73% |
|
+2.31% | +14.70% |
| 07-22 | Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications | CI |
| 06-29 | Valbiotis Raises EUR10 Million for Commercial Development, Working Capital | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 22.27M | - | ||||
| 68.52B | |||||
| 62.88B | |||||
| 28.13B | - | ||||
| 25.56B | |||||
| 24.65B | - |
- Stock Market
- Stocks
- ALVAL Stock
- Charts Valbiotis
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
